Back to Screener

Healthcare

VentriPoint Diagnostics Ltd.(VPTDF)

Live Price

Offline

$0.0876

+1.27% today

1Y Change

-22.44%

Window

Jun 23, 2025 โ†’ Jun 15, 2026

Market Cap
$30.00M
Revenue Growth
+93.5%
EPS Growth
0.0%
Dividend Yield
0.0%

Coverage: 248 bars ยท Jun 23, 2025 โ†’ Jun 15, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

VentriPoint Diagnostics Ltd. (VPTDF) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $0.09 and down 22.4% across the available one-year price window (Jun 23, 2025 โ†’ Jun 15, 2026). Baseline metrics include revenue growth of +93.5%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue +93.5%, EPS 0.0%, free cash flow +11.0% with operating margin -2113.8% and ROIC 157.5%. Valuation already assumes a fairly strong business story at price/sales 160.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VPTDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+93.5% vs +7.6% peer median

Operating Margin

Below sector median

-2113.8% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 28, 2026, but the surprise data is still limited.

The setup is mixed rather than one-directional

Revenue is +93.5% and EPS is 0.0%, while operating margin sits near -2113.8%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 2 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
May 28, 2026
โ€”-3.7%+0.6%โ€”
2026
May 1, 2026
โ€”-15.1%-22.1%-28.6%
2026
Apr 28, 2026
โ€”+16.3%+26.4%+22.7%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

VPTDF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

VPTDF Max Drawdown

-52.42%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for VPTDF and SPY.

Calendar-year return history is still loading or unavailable.
VentriPoint Diagnostics Ltd. logo

Company Overview

VentriPoint Diagnostics Ltd.

Other OTC

Toronto, ON, CA
Visit ventripoint.comCall IR+1 416 848 4510

Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model of the heart chamber using echocardiograms and magnetic resonance imaging images; and obtain reproducible, accurate volumetric measurement, and ejection fraction. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and Covid-19 related heart issues. The company was incorporated in 2004 and is based in Toronto, Canada.

Leadership
Hugh MacNaught
IPO Date
Sep 22, 2010
Street Address
18 Hook Avenue
Mailing
Toronto, ON, M6P 1T4
Region
Toronto, ON, CA
Reporting Currency
USD
Investor Line
+1 416 848 4510
Last Updated
May 5, 2026
ISIN: CA92281P2008
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
160.3
Price/Book
โ€”

Growth

Revenue
+93.5%
EPS
0.0%
Free Cash Flow
+11.0%

Profitability

Gross Margin
82.5%
Operating Margin
-2113.8%
Net Margin
-2311.8%
ROE
106.7%
ROIC
157.5%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
0.05

Earnings Reports

๐Ÿ“… Last reportedMay 28, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
May 28, 26
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
May 1, 26
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Apr 28, 26
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Nov 28, 25
-0.00
Est โ€”
โ€”
74.8B
Est โ€”
โ€”
โ€”
May 30, 25
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Apr 30, 25
-0.00
Est โ€”
โ€”
50.1B
Est โ€”
โ€”
โ€”
Apr 29, 25
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Nov 27, 24
-0.01
Est โ€”
โ€”
47.5B
Est โ€”
โ€”
โ€”
Aug 29, 24
-0.01
Est โ€”
โ€”
22.4B
Est โ€”
โ€”
โ€”
May 30, 24
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Apr 29, 24
-0.01
Est โ€”
โ€”
31.2B
Est โ€”
โ€”
โ€”
Nov 29, 23
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 6, 23
-0.01
Est โ€”
โ€”
2.9B
Est โ€”
โ€”
โ€”
Jun 1, 23
-0.01
Est โ€”
โ€”
2.9B
Est โ€”
โ€”
โ€”
May 4, 23
-0.01
Est โ€”
โ€”
20.9B
Est โ€”
โ€”
โ€”
Sep 30, 22
-0.01
Est โ€”
โ€”
11.3B
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks